PT - JOURNAL ARTICLE AU - Sediva, Anna AU - Orlicky, Martin AU - Vrabcova, Petra AU - Klocperk, Adam AU - Kalina, Tomas AU - Fujiwara, Hideji AU - Hsu, Fong-Fu AU - Bambouskova, Monika TI - Geranylgeraniol supplementation leads to an improvement in inflammatory parameters and reversal of the disease specific protein signature in patients with hyper-IgD syndrome AID - 10.1101/2024.07.17.24309492 DP - 2024 Jan 01 TA - medRxiv PG - 2024.07.17.24309492 4099 - http://medrxiv.org/content/early/2024/07/18/2024.07.17.24309492.short 4100 - http://medrxiv.org/content/early/2024/07/18/2024.07.17.24309492.full AB - Mevalonate kinase (MVK) deficiency, a rare autosomal recessive disease, significantly impacts metabolism and immunity, leading to mevalonic aciduria in severe cases and hyper-IgD syndrome (HIDS) in partial deficiency. These conditions arise due to disruptions in the mevalonate pathway, which is essential metabolic pathway responsible for the synthesis of non-sterol isoprenoids and other molecules. The resulting metabolic blockade triggers autoinflammatory responses, primarily due to deficient isoprenoid intermediates such as geranylgeranyl pyrophosphate (GGPP). This first reported pilot study evaluates the safety and efficacy of dietary geranylgeraniol supplementation (GG) in three patients with HIDS. Over three months, GG supplementation showed no liver toxicity and did not alter lipid profiles. Although GG did not rise the plasma levels of GGPP, the plasma proteomics showed significant changes induced by GG. Proteomic analysis further revealed that GG supplementation can reverse some of the features of HIDS-specific plasma protein signature, highlighting its potential to modulate inflammation and protein prenylation pathways. These findings suggest that GG supplementation could be a promising metabolic intervention to mitigate inflammation in HIDS, warranting further, more targeted investigation in larger clinical trials.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT06497829Funding StatementThis study was funded by internal grant, Motol University Hospital, Prague Czech Republic.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The pilot study was approved by the Ethical Committee, Motol University Hospital, Prague, Ref. Number EK 30/22, and by the Czech Agriculture and Food Inspection Authority who oversees the field of food supplements.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.